Saltar al contenido
Merck

Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone.

Nature biomedical engineering (2020-01-16)
Ryan Reshke, James A Taylor, Alexandre Savard, Huishan Guo, Luke H Rhym, Piotr S Kowalski, My Tran Trung, Charles Campbell, Wheaton Little, Daniel G Anderson, Derrick Gibbings
RESUMEN

A small percentage of the short interfering RNA (siRNA) delivered via passive lipid nanoparticles and other delivery vehicles reaches the cytoplasm of cells. The high doses of siRNA and delivery vehicle that are thus required to achieve therapeutic outcomes can lead to toxicity. Here, we show that the integration of siRNA sequences into a Dicer-independent RNA stem-loop based on pre-miR-451 microRNA-which is highly enriched in small extracellular vesicles secreted by many cell types-reduces the expression of the genes targeted by the siRNA in the liver, intestine and kidney glomeruli of mice at siRNA doses that are at least tenfold lower than the siRNA doses typically delivered via lipid nanoparticles. Small extracellular vesicles that efficiently package siRNA can significantly reduce its therapeutic dose.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Roche
ADNasa I, grade II, from bovine pancreas
Sigma-Aldrich
Seroalbúmina bovina, lyophilized powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Proteinasa K from Tritirachium album, lyophilized powder, BioUltra, ≥30 units/mg protein, for molecular biology
Sigma-Aldrich
1-β-D-Arabinofuranosylcytosine, Anticancer, antiviral agent that is especially effective against leukemias.